Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine in healthy Taiwanese children and adolescents.
OBJECTIVE
Disease caused by Bordetella pertussis is increasingly being identified among older children and adults in immunized populations, indicating a waning of the vaccine-induced immunity. These findings suggest the need for booster immunization of older children and adults. Modern acellular reduced-antigen-content vaccines have been developed, which can be given as a booster in individuals more than 4 years of age. This study was to assess the immunogenicity and reactogenicity of Boostrix, GlaxoSmithKline Biologicals' reduced-antigen-content diphtheria-tetanus acellular pertussis (dTpa) vaccine, when administered as a booster in healthy subjects previously primed with DTP vaccine.


METHODS
Healthy Taiwanese children and adolescents aged 6-8 years and 15-20 years, previously primed with DTP vaccine, were enrolled. All received one dose of Boostrix. Two blood samples were taken from each of them, one before vaccination and one at 1 month after vaccination. Serum antibodies to diphtheria and tetanus toxoids and immunoglobulin G (IgG) antibodies against the pertussis components PT, FHA and PRN were measured by enzyme-linked immunosorbent assay (ELISA) technique. Adverse reactions following vaccination were recorded.


RESULTS
A total of 180 subjects were recruited. The vaccine response rates to the pertussis antigens ranged between 89.0-100%. There were no serious adverse events reported during the study period.


CONCLUSIONS
The results of this study suggest that Boostrix may be safely and effectively administered as a booster dose to children previously primed with DTP vaccine.
Huang
Li-Min
LM
Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.
Chang
Luan-Yin
LY
Tang
Haiwen
H
Bock
Hans L
HL
Lu
Chun-Yi
CY
Huang
Fu-Yuan
FY
Lin
Tzou-Yien
TY
Lee
Chin-Yun
CY
D000293:Adolescent; D000328:Adult; D000917:Antibody Formation; D000942:Antigens, Bacterial / Q000276:immunology*; D002648:Child; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000009:adverse effects* / Q000276:immunology*; D005260:Female; D006801:Humans; D007117:Immunization, Secondary; D007074:Immunoglobulin G / Q000032:analysis; D008297:Male; D013624:Taiwan
D000942:Antigens, Bacterial; C505143:Boostrix; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D007074:Immunoglobulin G